The aim was to determine if the GnRH agonist-only triggers had provided outcomes comparable to dual trigger, while minimizing the risk of ovarian hyperstimulation syndrome (OHSS). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.